ArticleInternational journal of nanomedicine2021
Cancer Cell-Membrane Biomimetic Boron Nitride Nanospheres for Targeted Cancer Therapy.
Article in International journal of nanomedicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Current perspectives and trends in nanoparticle drug delivery systems in breast cancer: bibliometric analysis and review.Frontiers in bioengineering and biotechnology · 2023Pooled it
- Advanced Drug Delivery Strategies for Overcoming Biological Barriers: Tumor Microenvironment and Blood-Brain Barrier.Drugs in R&D · 2026Review
- Cancer Cell Membrane-Coated NPs as a Biomimetic Strategy for Precision Tumor Therapy.Pharmaceutics · 2025Review
- Nanomaterial Delivery Vehicles for the Development of Neoantigen Tumor Vaccines for Personalized Treatment.Molecules (Basel, Switzerland) · 2024Review
- Microglia Polarization and Antiglioma Effects Fostered by Dual Cell Membrane-Coated Doxorubicin-Loaded Hexagonal Boron Nitride Nanoflakes.ACS applied materials & interfaces · 2023Article
- Cell membrane-coated nanomaterials for cancer therapy.Materials today. Bio · 2023Review
- Boron-Containing Compounds for Prevention, Diagnosis, and Treatment of Human Metabolic Disorders.Biological trace element research · 2023Review
- Stimuli-Responsive Boron-Based Materials in Drug Delivery.International journal of molecular sciences · 2023Review
- Cancer Cell Membrane-Coated Gambogic Acid Nanoparticles for Effective Anticancer Vaccination by Activating Dendritic Cells.International journal of nanomedicine · 2023Article
- Toxicokinetics, dose-response, and risk assessment of nanomaterials: Methodology, challenges, and future perspectives.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2022Review
- The Current State of the Art in PARP Inhibitor-Based Delivery Nanosystems.Pharmaceutics · 2022Review
- Cell membrane coated-nanoparticles for cancer immunotherapy.Acta pharmaceutica Sinica. B · 2022Review
- Research progress in inducing immunogenic cell death of tumor cells.Frontiers in immunology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeNanomaterial-based drug-delivery systems allowing for effective targeted delivery of smallmolecule chemodrugs to tumors have revolutionized cancer therapy. Recently, as novel nanomaterials with outstanding physicochemical properties, boron nitride nanospheres (BNs) have emerged as a promising candidate for drug delivery. However, poor dispersity and lack of tumor targeting severely limit further applications. In this study, cancer cell-membrane biomimetic BNs were designed for targeted anticancer drug delivery.
methodsCell membrane extracted from HeLa cells (HM) was used to encapsulate BNs by physical extrusion. Doxorubicin (Dox) was loaded onto HM-BNs as a model drug.
resultsThe cell-membrane coating endowed the BNs with excellent dispersibility and cytocompatibility. The drug-release profile showed that the Dox@HM-BNs responded to acid pH, resulting in rapid Dox release. Enhanced cellular uptake of Dox@HM-BNs by HeLa cells was revealed because of the homologous targeting of cancer-cell membranes. CCK8 and live/dead assays showed that Dox@HM-BNs had stronger cytotoxicity against HeLa cells, due to self-selective cellular uptake. Finally, antitumor investigation using the HeLa tumor model demonstrated that Dox@HM-BNs possessed much more efficient tumor inhibition than free Dox or Dox@BNs.
conclusionThese findings indicate that the newly developed HM-BNs are promising as an efficient tumor-selective drug-delivery vehicle for tumor therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.